medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2022-3-8-13medalphabet-2539Research ArticleСтатьиЛекарственно-индуцированная артериальная гипертензияDrug-induced hypertensionhttps://orcid.org/0000-0002-0795-8225ОстроумоваО. Д.OstroumovaO. D.

Остроумова Ольга Дмитриевна, д.м.н., проф., зав. кафедрой терапии и полиморбидной патологии имени академика М. С. Вовси, ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования»; проф. кафедры клинической фармакологии и пропедевтики внутренних болезней, ФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова» Минздрава России (Сеченовский университет)

eLibrary: 3910–6585

Москва

Ostroumova Olga D., DM Sci. (habil.), professor, head of Dept of Therapy and Polymorbid Pathology n.a. academician M.S. Vovsi, Russian Medical Academy for Continuing Professional Education

eLibrary: 3910–6585

Moscow

ostroumova.olga@mail.ruhttps://orcid.org/0000-0002-4496-3680СычевД. А.SychevD. A.

Сычев Дмитрий Алексеевич, д.м.н., проф., проф. РАН, чл.- корр. РАН, ректор

eLibrary: 4525–7556

Москва

Sychev Dmitry A., DM Sci. (habil.), professor, RAS professor, RAS corresponding member, rector

eLibrary: 4525–7556

Moscow

dimasychev@mail.ruhttps://orcid.org/0000-0001-5801-3742КочетковА. И.KochetkovA. I.

Кочетков Алексей Иванович, к.м.н., доцент кафедры терапии и полиморбидной патологии имени академика М. С. Вовси

eLibrary: 9212–6010

Москва

Kochetkov Alexei I., PhD Med, assistant professor at Dept of Therapy and Polymorbid Pathology n. a. academician M. S. Vovsi

eLibrary: 9212–6010

Moscow

ak_info@list.ruhttps://orcid.org/0000-0003-1499-247XОстроумоваТ. М.OstroumovaT. M.

Остроумова Татьяна Максимовна, к.м.н., ассистент кафедры нервных болезней и нейрохирургии лечебного факультета

eLibrary: 5043–4713

Москва

Ostroumova Tatyana M., PhD Med, assistant of Dept of Nervous Diseases and Neurosurgery, Faculty of Medicine

eLibrary: 5043–4713

Moscow

t.ostroumova3@gmail.comhttps://orcid.org/0000-0001-5107-8834КуликоваМ. И.KulikovaM. I.

Куликова Мария Игоревна, врач-терапевт

Москва

Kulikova Mariya I., therapist

Moscow

mariakulikova123@yandex.ruhttps://orcid.org/0000-0002-3900-758XДеВ. А.DeV. A.

Де Валерия Анатольевна, ординатор II года кафедры терапии и полиморбидной патологии имени академика М. С. Вовси

Москва

De Valeria A., 2nd year resident of Dept of Therapy and Polymorbid Pathology n.a.  academician M. S. Vovsi

Moscow

devaleria97@mail.ruФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова» Минздрава России (Сеченовский университет)РоссияRussian Medical Academy for Continuing Professional Education; I. M. Sechenov First Moscow State Medical University (Sechenov University)Russian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования»РоссияRussian Medical Academy for Continuing Professional EducationRussian FederationФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова» Минздрава России (Сеченовский университет)РоссияI. M. Sechenov First Moscow State Medical University (Sechenov University)Russian Federation20221504202203Современная поликлиника (1)813Copyright © Остроумова О.Д., Сычев Д.А., Кочетков А.И., Остроумова Т.М., Куликова М.И., Де В.А., 20222022Остроумова О.Д., Сычев Д.А., Кочетков А.И., Остроумова Т.М., Куликова М.И., Де В.А.Ostroumova O.D., Sychev D.A., Kochetkov A.I., Ostroumova T.M., Kulikova M.I., De V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2539

Применение лекарственных средств (ЛС) может приводить к развитию лекарственно-индуцированной (ЛИ) артериальной гипертензии (АГ). Цель работы – систематизация и анализ данных научной литературы о ЛС, применение которых может вызвать развитие ЛИ АГ, а также об эпидемиологии, патофизиологических механизмах, факторах риска, клинической картине, диагностике и дифференциальной диагностике, лечении и профилактике ЛИ АГ. В результате анализа данных выявлено, что ЛС, такие как глюкокортикостероиды, противоопухолевые препараты, иммуносупрессанты, нестероидные противовоспалительные средства, антидепрессанты и некоторые другие, связаны с развитием АГ. Механизмы развития ЛИ АГ полностью не установлены и нуждаются в дальнейшем изучении. ЛИ АГ попрежнему остается одной из самых распространенных и зачастую нераспознанной нежелательной реакцией (НР) ЛС. Клинические проявления ЛИ АГ неспецифичны. Пациент может предъявлять жалобы, связанные с поражением органов-мишеней или осложнениями АГ – жалобы на головные боли, тошноту, головокружение, помутнение зрения, тревожность, одышку и др. Поэтому всегда необходимо обращать внимание на анамнез пациента, принимаемые им ЛС, резкие повышения давления у пациентов с ранее хорошо контролируемой АГ или случаи неконтролируемой АГ.

Some drugs can lead to the development of drug-induced arterial hypertension. The aim of the work is to systematize and analyze the data about drugs that can cause the development of drug-induced hypertension, as well as on epidemiology, pathophysiological mechanisms, risk factors, clinical picture, diagnosis and differential diagnosis, treatment and prevention of drug-induced hypertension. As a result of data analysis, it was revealed that drugs: glucocorticosteroids, antineoplastic drugs, immunosuppressants, nonsteroidal anti-inflammatory drugs, antidepressants and some others are associated with the development of hypertension. The mechanisms of development of drug-induced arterial hypertension are not fully established and require further study. Drug-induced arterial hypertension is still one of the most common and often unrecognized adverse reactions. The clinical manifestations of drug-induced hypertension are not specific. The symptoms are associated with target organ damage or complications of hypertension and may include a headache, nausea, dizziness, blurred vision, anxiety, shortness of breath, etc. patients with previously well-controlled hypertension or cases of uncontrolled hypertension. Therefore, it is always necessary to pay attention to the patient’s history, pharmacological anamnesis, rapid increases in blood pressure in patients with previously well-controlled hypertension, or cases of uncontrolled hypertension.

лекарственно-индуцированные заболеванияартериальная гипертензияфакторы рисканежелательные реакцииартериальное давлениеdrug-induced diseasesarterial hypertensionrisk factorsside effectsblood pressureReferencesКлинические рекомендации. Артериальная гипертензия у взрослых (МКБ 10: I10/I11/I12/I13/I15) 2020. ID: КР62. https://cr.minzdrav.gov.ru/schema/62_2. Дата обращения: 29.12.2021.Clinical guidelines. Arterial hypertension in adults. 2020. ID: КР62. Available: https://cr.minzdrav.gov.ru/schema/62_2. Accessed: 29.12.2021. (In Russ.)Бойцов СА, Баланова ЮА, Шальнова СА, Деев АД, Артамонова ГВ, Гатагонова ТМ и др. Артериальная гипертония среди лиц 25–64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014; 13 (4): 4–14. https://doi.org/10.15829/1728–8800–2014–4–4–14.Boytsov SA, Balanova YuA, Shalnova SA, Deev AD, Artamonova GV, Gatagonova TM, et al. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2014; 13 (4): 4–14. (In Russ.) https://doi.org/10.15829/1728–8800–2014–4–4–14.Муромцева ГА, Концевая АВ, Константинов ВВ, Артамонова ГВ, Гатагонова ТМ, Дупляков ДВ и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012–2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014; 13 (6): 4–11. https://doi.org/10.15829/1728–8800–2014–6–4–11Muromtseva GA, Kontsevaya AV, Konstantinov VV, Artamonova GV, Gatagonova TM, Duplyakov DV, et al. The prevalence of non-infectious diseases risk factors in Russian population in 2012–2013 years. The results of ECVD-RF. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2014; 13 (6): 4–11. (In Russ.) https://doi.org/10.15829/1728–8800–2014–6–4–11Tisdale JE, Miller DA. Drug Induced Diseases: Prevention, Detection, and Management. 3rd Ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018; 1399 р.Tisdale JE, Miller DA. Drug Induced Diseases: Prevention, Detection, and Management. 3rd Ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018; 1399 р.Остроумова ОД, Куликова МИ. Лекарственно-индуцированная артериальная гипертония. Системные гипертензии. 2019; 16 (2): 32–41. https://doi.org/10.26442/2075082X.2019.2.180164Ostroumova OD, Kulikova MI. Drug-induced arterial hypertension. Sistemnye gipertenzii = Systemic Hypertension. 2019; 16 (2): 32–41. (In Russ.) https://doi.org/10.26442/2075082X.2019.2.180164Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39 (33): 3021–104. https://doi.org/10.1093/eurheartj/ehy339Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39 (33): 3021–104. https://doi.org/10.1093/eurheartj/ehy339van Dorst DCH, Dobbin SJH, Neves KB, Herrmann J, Herrmann SM, Versmissen J, et al. Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. Circulation Research. 2021; 128 (7): 1040–61. https://doi.org/10.1161/circresaha.121.318051van Dorst DCH, Dobbin SJH, Neves KB, Herrmann J, Herrmann SM, Versmissen J, et al. Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. Circulation Research. 2021; 128 (7): 1040–61. https://doi.org/10.1161/circresaha.121.318051Ruf R, Yarandi N, Ortiz-Melo DI, Sparks MA. Onco-hypertension: Overview of hypertension with anti-cancer agents. Journal of Onco-Nephrology. 2021; 5 (1): 57–69. https://doi.org/10.1177%2F23993693211001374Ruf R, Yarandi N, Ortiz-Melo DI, Sparks MA. Onco-hypertension: Overview of hypertension with anti-cancer agents. Journal of Onco-Nephrology. 2021; 5 (1): 57–69. https://doi.org/10.1177%2F23993693211001374Mohammed T, Singh M, Tiu JG, Kim AS. Etiology and management of hypertension in patients with cancer. Cardio-Oncology. 2021; 7 (1): 14. https://doi.org/10.1186/s40959–021–00101–2Mohammed T, Singh M, Tiu JG, Kim AS. Etiology and management of hypertension in patients with cancer. Cardio-Oncology. 2021; 7 (1): 14. https://doi.org/10.1186/s40959–021–00101–2Samuels JA, Franco K, Wan F, Sorof JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol. 2006; 21 (1): 92–5. https://doi.org/10.1007/s00467–005–2051–1Samuels JA, Franco K, Wan F, Sorof JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol. 2006; 21 (1): 92–5. https://doi.org/10.1007/s00467–005–2051–1Lester SJ, Baggott M, Welm S, Schiller NB, Jones RT, Foster E, et al. Cardiovascular Effects of 3,4-Methylenedioxymethamphetamine: A Double-Blind, Placebo-Controlled Trial. Ann Intern Med. 2000; 133 (12): 969–73. https://doi.org/10.7326/0003–4819–133–12–200012190–00012Lester SJ, Baggott M, Welm S, Schiller NB, Jones RT, Foster E, et al. Cardiovascular Effects of 3,4-Methylenedioxymethamphetamine: A Double-Blind, Placebo-Controlled Trial. Ann Intern Med. 2000; 133 (12): 969–73. https://doi.org/10.7326/0003–4819–133–12–200012190–00012Pande A, Lombardo J, Spangenthal E, Javle M. Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res. 2007; 27 (5B): 3465–70.Pande A, Lombardo J, Spangenthal E, Javle M. Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res. 2007; 27 (5B): 3465–70.Rasier R, Artunay O, Yuzbasioglu E, Sengul A, Bahcecioglu H. The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye (Lond). 2009; 23 (8): 1714–8. https://doi.org/10.1038/eye.2008.360Rasier R, Artunay O, Yuzbasioglu E, Sengul A, Bahcecioglu H. The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye (Lond). 2009; 23 (8): 1714–8. https://doi.org/10.1038/eye.2008.360Rosiak J, Sadowski L. Hypertension associated with bevacizumab. Clin J Oncol Nurs. 2005; 9 (4): 407–11. https://doi.org/10.1188/05.CJON.407–411Rosiak J, Sadowski L. Hypertension associated with bevacizumab. Clin J Oncol Nurs. 2005; 9 (4): 407–11. https://doi.org/10.1188/05.CJON.407–411Zhu X, Wu S, Dahut LW, Parikh Ch R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007; 49 (2): 186–93. https://doi.org/10.1053/j.ajkd.2006.11.039Zhu X, Wu S, Dahut LW, Parikh Ch R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007; 49 (2): 186–93. https://doi.org/10.1053/j.ajkd.2006.11.039Roose SP, Dalack GW, Glassman AH. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry. 1991; 148 (4): 512–6. https://doi.org/10.1176/ajp.148.4.512Roose SP, Dalack GW, Glassman AH. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry. 1991; 148 (4): 512–6. https://doi.org/10.1176/ajp.148.4.512Whelton A, Schulman G, Wallmark C, Drower EJ, Isakson PC, Verburg KM, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med. 2000; 160 (10): 1465–70. https://doi.org/10.1001/archinte.160.10.1465Whelton A, Schulman G, Wallmark C, Drower EJ, Isakson PC, Verburg KM, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med. 2000; 160 (10): 1465–70. https://doi.org/10.1001/archinte.160.10.1465Whelton A, White WB, Bello AE, Puma JA, Fort JG, SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002; 90 (9): 959–63. https://doi.org/10.1016/s0002–9149(02)02661–9Whelton A, White WB, Bello AE, Puma JA, Fort JG, SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002; 90 (9): 959–63. https://doi.org/10.1016/s0002–9149(02)02661–9Weaver A, Alderman M, Sperling R. Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 inhibitors celecocxib versus rofecoxib in patients with systemic hypertension and osteoartthritis. Am J Cardiol. 2003; 91 (10): 1291–2.Weaver A, Alderman M, Sperling R. Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 inhibitors celecocxib versus rofecoxib in patients with systemic hypertension and osteoartthritis. Am J Cardiol. 2003; 91 (10): 1291–2.Wolfe F, Zhao S, Pettitt D. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal anti-inflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. J Rheumatol. 2004; 31 (6): 1143–51.Wolfe F, Zhao S, Pettitt D. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal anti-inflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. J Rheumatol. 2004; 31 (6): 1143–51.Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005; 352 (11): 1071–80. https://doi.org/10.1056/NEJMoa050405Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005; 352 (11): 1071–80. https://doi.org/10.1056/NEJMoa050405Nzerue CM, Hewan-Lowe K, Riley LJ Jr. Cocain and the kidney: a synthesis of pathophysiologic and clinical perspectives. Am J Kidney Dis. 2000; 35 (5): 783–95. https://doi.org/10.1016/s0272–6386(00)70246–0Nzerue CM, Hewan-Lowe K, Riley LJ Jr. Cocain and the kidney: a synthesis of pathophysiologic and clinical perspectives. Am J Kidney Dis. 2000; 35 (5): 783–95. https://doi.org/10.1016/s0272–6386(00)70246–0Hussain RM, McIntosh Sj, Lawson J, Kenny RA. Fludrocortisone in the treatment of hypotensive disorders in the elderly. Heart. 1996; 76 (6): 507–9. https://doi.org/10.1136/hrt.76.6.507Hussain RM, McIntosh Sj, Lawson J, Kenny RA. Fludrocortisone in the treatment of hypotensive disorders in the elderly. Heart. 1996; 76 (6): 507–9. https://doi.org/10.1136/hrt.76.6.507Chobanian AV, Volicer L, Tiffit CP, Gavras H, Liang CS, Faxon D. Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med. 1979; 301 (2): 68–73. https://doi.org/10.1056/NEJM197907123010202Chobanian AV, Volicer L, Tiffit CP, Gavras H, Liang CS, Faxon D. Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med. 1979; 301 (2): 68–73. https://doi.org/10.1056/NEJM197907123010202Sherwood H, Epstein J, Maurer MI, Blau S, Kanof NB, Zucker A. Intramuscular triamcinolone acetonide for the treatment of allergic and cutaneous diseases: report of 582 patients. Curr Ther Res Clin Exp. 1967; 9 (3): 114–30Sherwood H, Epstein J, Maurer MI, Blau S, Kanof NB, Zucker A. Intramuscular triamcinolone acetonide for the treatment of allergic and cutaneous diseases: report of 582 patients. Curr Ther Res Clin Exp. 1967; 9 (3): 114–30Hari P, Bagga A, Mantan M. Short term efficacy of intravenous dexamethasone and methylprednisolone therapy in steroid resistant nephrotic syndrome. Indian Pediatr. 2004; 41 (10): 993–1000Hari P, Bagga A, Mantan M. Short term efficacy of intravenous dexamethasone and methylprednisolone therapy in steroid resistant nephrotic syndrome. Indian Pediatr. 2004; 41 (10): 993–1000Ferrari P. Cortisol and the renal handling of electrolytes: role in glucocorticoid-induced hypertension and bone disease. Best Pract Res Clin Endocrinol Metab. 2003; 17 (4): 575–89. https://doi.org/10.1016/s1521–690x(03)00053–8Ferrari P. Cortisol and the renal handling of electrolytes: role in glucocorticoid-induced hypertension and bone disease. Best Pract Res Clin Endocrinol Metab. 2003; 17 (4): 575–89. https://doi.org/10.1016/s1521–690x(03)00053–8Whitworth JA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int. 1987; 31 (5): 1213–24. https://doi.org/10.1038/ki.1987.131Whitworth JA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int. 1987; 31 (5): 1213–24. https://doi.org/10.1038/ki.1987.131Bennett WM, Porter GA. Cyclosporine-associated hypertension. Am J Med. 1988; 85 (2): 131–3. https://doi.org/10.1016/s0002–9343(88)80330–9Bennett WM, Porter GA. Cyclosporine-associated hypertension. Am J Med. 1988; 85 (2): 131–3. https://doi.org/10.1016/s0002–9343(88)80330–9Vercauteren SB, Bosmans JL, Elseviers MM, Verpooten GA, De Broe ME. A metaanalysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases. Kidney Int. 1998; 54 (2): 536–45. https://doi.org/10.1046/j.1523–1755.1998.00017.xVercauteren SB, Bosmans JL, Elseviers MM, Verpooten GA, De Broe ME. A metaanalysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases. Kidney Int. 1998; 54 (2): 536–45. https://doi.org/10.1046/j.1523–1755.1998.00017.xCharnick SB, Nedelman JR, Chang CT, Hwang DS, Jin J, Moore MA, et al. Description of blood pressure changes in patients beginning cyclosporin A therapy. Ther Drug Monit. 1997; 19 (1): 17–24. https://doi.org/10.1097/00007691–199702000–00003Charnick SB, Nedelman JR, Chang CT, Hwang DS, Jin J, Moore MA, et al. Description of blood pressure changes in patients beginning cyclosporin A therapy. Ther Drug Monit. 1997; 19 (1): 17–24. https://doi.org/10.1097/00007691–199702000–00003Fung JJ, Todo S, Jain A, Alessiani M, Scotti C, Starzl TE, et al. Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc. 1990 Feb; 22 (1): 6–12.Fung JJ, Todo S, Jain A, Alessiani M, Scotti C, Starzl TE, et al. Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc. 1990 Feb; 22 (1): 6–12.Jonson AG. NSAIDs and blood pressure: clinical importance for older patients. Drugs Aging. 1998; 12 (1): 17–27. https://doi.org/10.2165/00002512–199812010–00003Jonson AG. NSAIDs and blood pressure: clinical importance for older patients. Drugs Aging. 1998; 12 (1): 17–27. https://doi.org/10.2165/00002512–199812010–00003Jonson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994; 121 (4): 289–300. https://doi.org/10.7326/0003–4819–121–4–199408150–00011Jonson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994; 121 (4): 289–300. https://doi.org/10.7326/0003–4819–121–4–199408150–00011Gurwich JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H, et al. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA. 1994; 272 (10): 781–6.Gurwich JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H, et al. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA. 1994; 272 (10): 781–6.MacFarlane LL, Orak DJ, Simpson WM. NSAIDs, antihypertensive agents and loss of blood pressure control. Am Fam Physician. 1995; 51 (4): 849–56.MacFarlane LL, Orak DJ, Simpson WM. NSAIDs, antihypertensive agents and loss of blood pressure control. Am Fam Physician. 1995; 51 (4): 849–56.Mene P, Pugliese F, Patrono C. The effects of nonsteroidal anti-inflammatory drugs on human hypertensive vascular disease. Semin Nephrol. 1995; 15 (3): 244–52.Mene P, Pugliese F, Patrono C. The effects of nonsteroidal anti-inflammatory drugs on human hypertensive vascular disease. Semin Nephrol. 1995; 15 (3): 244–52.US Food and Drug Administration Center for Drug Evaluation and Research. Medication Guide for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). May 2016. Available: https://www.fda.gov/media/72932/download. Accessed: 21.12.2021.US Food and Drug Administration Center for Drug Evaluation and Research. Medication Guide for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). May 2016. Available: https://www.fda.gov/media/72932/download. Accessed: 21.12.2021.Lai YK. Adverse effect of intraoperative phenylephrine 10%: case report. Br J Ophthalmol. 1989; 73 (6): 468–9. https://doi.org/10.1136/bjo.73.6.468Lai YK. Adverse effect of intraoperative phenylephrine 10%: case report. Br J Ophthalmol. 1989; 73 (6): 468–9. https://doi.org/10.1136/bjo.73.6.468Fraunfelder FW, Fraunfelder FT, Jensvold B. Adverse systemic effects from pledgets of topical ocular phenylephrine 10 %. Am J Ophthalmol. 2002; 134 (4): 624–5. https://doi.org/10.1016/s0002–9394(02)01591-xFraunfelder FW, Fraunfelder FT, Jensvold B. Adverse systemic effects from pledgets of topical ocular phenylephrine 10 %. Am J Ophthalmol. 2002; 134 (4): 624–5. https://doi.org/10.1016/s0002–9394(02)01591-xJordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM, et al. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes (Lond). 2005; 29 (5): 509–16. https://doi.org/10.1038/sj.ijo.0802887Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM, et al. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes (Lond). 2005; 29 (5): 509–16. https://doi.org/10.1038/sj.ijo.0802887Kim SH, Lee YM, Jee SH, Jee SH, Nam Ch M. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res. 2003; 11 (9): 1116–23. https://doi.org/10.1038/oby.2003.152Kim SH, Lee YM, Jee SH, Jee SH, Nam Ch M. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res. 2003; 11 (9): 1116–23. https://doi.org/10.1038/oby.2003.152Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, et al. Blood pressure changes associated with sibutramine and weight management – an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). Diabetes Obes Metab. 2009; 11 (3): 239–50.Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, et al. Blood pressure changes associated with sibutramine and weight management – an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). Diabetes Obes Metab. 2009; 11 (3): 239–50.Lean M. Sibutramine – a review of clinical efficacy. Int J Obes Relat Metab Disord. 1997; 21 Suppl 1: S 30–6; discussion 37–9. https://doi.org/10.1111/j.1463–1326.2008.00930.xLean M. Sibutramine – a review of clinical efficacy. Int J Obes Relat Metab Disord. 1997; 21 Suppl 1: S 30–6; discussion 37–9. https://doi.org/10.1111/j.1463–1326.2008.00930.xPerrio MJ, Wilton LV, Shakir SA. The safety profiles of orlistat and Sibutramine: Results of Prescription-Event Monitoring Studies in England. Obesity. 2007; 15 (11): 2712–22. https://doi.org/10.1038/oby.2007.323Perrio MJ, Wilton LV, Shakir SA. The safety profiles of orlistat and Sibutramine: Results of Prescription-Event Monitoring Studies in England. Obesity. 2007; 15 (11): 2712–22. https://doi.org/10.1038/oby.2007.323Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension, with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008; 9 (2): 117–23. https://doi.org/10.1016/S1470–2045(08)70003–2Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension, with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008; 9 (2): 117–23. https://doi.org/10.1016/S1470–2045(08)70003–2Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol. 2007; 18 (10): 1745–7. https://doi.org/10.1093/annonc/mdm454Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol. 2007; 18 (10): 1745–7. https://doi.org/10.1093/annonc/mdm454Chu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009; 48 (1): 9–17. https://doi.org/10.1080/02841860802314720Chu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009; 48 (1): 9–17. https://doi.org/10.1080/02841860802314720Pham SM, Kormos RL, Hattler BG, Kawai A, Tsamandas AC, Demetris AJ, et al. A prospective trial of tacpolimus (FK 506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg. 1996; 111 (4): 764–72.Pham SM, Kormos RL, Hattler BG, Kawai A, Tsamandas AC, Demetris AJ, et al. A prospective trial of tacpolimus (FK 506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg. 1996; 111 (4): 764–72.Jain A, Reyes J, Kashyap R, Rohal S, Cacclarelli T, McMichael J, et al. Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. Transplant Proc. 1998; 30 (4): 1403–4.Jain A, Reyes J, Kashyap R, Rohal S, Cacclarelli T, McMichael J, et al. Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. Transplant Proc. 1998; 30 (4): 1403–4.Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998; 59 (10): 502–8.Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998; 59 (10): 502–8.Кулаков ВИ, Кулаков ВИ, Сметник ВП. Руководство по климактерию. М.: Медицинское информационное агентство, 2001; с. 404–95.Kulakov VI, Kulakov VI, Smetnik VP. Menopause Guide. Moscow: Medical Information Agency, 2001; 404–95. (In Russ.)Барт БЯ, Бороненков ГМ, Беневская ВФ. Артериальная гипертония у женщин в постменопаузе: современные возможности медикаментозной терапии в поликлинических условиях. Российский кардиологический журнал. 2001; (5): 69–70.Bart BYa, Boronenkov GM, Benevskaya VF. Arterial hypertension in postmenopausal women: modern possibilities of drug therapy in outpatient clinics. Rossijskij kardiologicheskij zhurnal = Russian Cardiology Journal. 2001; (5): 69–70. (In Russ.)Diaconu CC, Dediu GN, Lancu MA. Drug-induced arterial hypertension – a frequently ignored cause of secondary hypertension: a review. Acta Cardiol. 2018; 1: 1–7. https://doi.org/10.1080/00015385.2017.1421445Diaconu CC, Dediu GN, Lancu MA. Drug-induced arterial hypertension – a frequently ignored cause of secondary hypertension: a review. Acta Cardiol. 2018; 1: 1–7. https://doi.org/10.1080/00015385.2017.1421445Сычев ДА, Остроумова ОД, Переверзев АП, Кочетков АИ, Остроумова ТМ, Клепикова МВ и др. Лекарственно-индуцированные заболевания: подходы к диагностике, коррекции и профилактике. Фармаконадзор. Фарматека. 2020; 27 (6): 113–26.Sychev DA, Ostroumova OD, Pereverzev AP, Kochetkov AI, Ostroumova TM, Klepikova MV et al. Drug-induced diseases: approaches to diagnosis, correction and prevention. Pharmacovigilance. Farmateka = Pharmateca. 2020; 27 (6): 113–26. (In Russ.) https://doi:10.18565/pharmateca.2020.6.113–126.Naranjo СA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2): 239–45. https://doi.org/10.1038/clpt.1981.154Naranjo СA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2): 239–45. https://doi.org/10.1038/clpt.1981.154

The authors declare that there are no conflicts of interest present.